公开(公告)号：US20240335510A1

公开(公告)日：2024-10-10

申请号：US18746819

申请日：2024-06-18

Applicant: CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES ,  HUMANITAS MIRASOLE SPA ,  The University of Sussex ,  King's College London ,  Queen Mary University of London ,  Sorbonne Universite ,  Assistance Publique-Hopitaux De Paris ,  The University of Sheffield

Inventor： Gilbert Bensimon ,  Peter Nigel Leigh ,  Timothy Tree ,  Cecilia Garlanda ,  Massimo Locati ,  Janine Kirby ,  Pamela Shaw ,  Andrea Malaspina

IPC: A61K38/20 ,  A61K31/428 ,  A61P25/28

CPC classification number: A61K38/2013 ,  A61K31/428 ,  A61P25/28

Abstract: The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

公开(公告)号：US20230090069A1

公开(公告)日：2023-03-23

申请号：US17904734

申请日：2021-03-05

Applicant: CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES ,  HUMANITAS MIRASOLE SPA ,  THE UNIVERSITY OF SUSSEX ,  KING'S COLLEGE LONDON ,  QUEEN MARY UNIVERSITY OF LONDON ,  SORBONNE UNIVERSITE ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  THE UNIVERSITY OF SHEFFIELD

Inventor： Gilbert BENSIMON ,  Peter Nigel LEIGH ,  Timothy TREE ,  Cecilia GARLANDA ,  Massimo LOCATI ,  Janine KIRBY ,  Pamela SHAW ,  Andrea MALASPINA

IPC: A61K38/20 ,  A61K31/428 ,  A61P25/28

Abstract: The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU) Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 HI human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.